JJIJ
PTGX icon

Johnson & Johnson Innovation - JJDC’s Protagonist Therapeutics PTGX Stock Holding History

Johnson & Johnson Innovation - JJDC’s Portfolio PTGX Stock Details PTGX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q2 		$110M Hold
2,449,183
– – 11.24% 3
2021
Q1 		$63.4M Hold
2,449,183
– – 8.22% 3
2020
Q4 		$49.4M Hold
2,449,183
– – 6.37% 3
2020
Q3 		$47.9M Hold
2,449,183
– – 9.64% 4
2020
Q2 		$43.3M Hold
2,449,183
– – 8.5% 5
2020
Q1 		$17.3M Hold
2,449,183
– – 9.41% 3
2019
Q4 		$17.3M Buy
+2,449,183
New +$24.3M 6.23% 3

Other funds holding PTGX

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
CCM
Consonance Capital Management New York $7.28M AUM 43.59% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
DM
Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return

Johnson & Johnson Innovation - JJDC's PTGX Position: Q2 2021 in Review

Johnson & Johnson Innovation - JJDC held its Protagonist Therapeutics (PTGX) position steady in Q2 2021 at 2,449,183 shares worth $110M. The position accounts for 11.24% of the portfolio, ranked #3.

Johnson & Johnson Innovation - JJDC first reported a position in PTGX in Q4 2019 and has held it in 7 quarters since. 138 funds tracked by Wall St. Rank hold PTGX as of Q2 2021.

  • Johnson & Johnson Innovation - JJDC held 2,449,183 shares of Protagonist Therapeutics worth $110M as of Q2 2021.
  • Johnson & Johnson Innovation - JJDC left its Protagonist Therapeutics share count unchanged in Q2 2021.
  • Protagonist Therapeutics made up 11.24% of Johnson & Johnson Innovation - JJDC's portfolio in Q2 2021, its #3 holding.
  • Johnson & Johnson Innovation - JJDC first reported a position in Protagonist Therapeutics in Q4 2019 and has held it in 7 quarters since.
  • 138 funds tracked by Wall St. Rank held Protagonist Therapeutics as of Q2 2021.

Based on Johnson & Johnson Innovation - JJDC's 13F filing for Q2 2021, filed 3 Aug 2021.